Dj Seelos Therapeutics Inc Com, Inst Holders, 4Q 2024 (Seelq)

Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Consumer Services, Financials and Industrials sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average lost 1.01%, while the S&P 500 index lost 0.43%, and the NASDAQ Composite index lost 0.47%.

The best performers of the session on the Dow Jones Industrial Average were Merck & Company Inc (NYSE:MRK), which rose 2.43% or 2.08 points to trade at 87.68 at the close. Meanwhile, Amgen Inc (NASDAQ:AMGN) added 1.24% or 3.66 points to end at 297.93 and Verizon Communications Inc (NYSE:VZ) was up 1.14% or 0.48 points to 42.49 in late trade.

The worst performers of the session were Walmart Inc (NYSE:WMT), which fell 6.53% or 6.79 points to trade at 97.21 at the close. JPMorgan Chase & Co (NYSE:JPM) declined 4.46% or 12.45 points to end at 266.80 and Goldman Sachs Group Inc (NYSE:GS) was down 3.87% or 25.89 points to 642.26.

The top performers on the S&P 500 were Hasbro Inc (NASDAQ:HAS) which rose 12.95% to 69.06, Baxter International Inc (NYSE:BAX) which was up 8.50% to settle at 33.44 and LKQ Corporation (NASDAQ:LKQ) which gained 5.96% to close at 41.75.

The worst performers were EPAM Systems Inc (NYSE:EPAM) which was down 12.80% to 225.07 in late trade, Axon Enterprise Inc (NASDAQ:AXON) which lost 8.70% to settle at 541.81 and Royal Caribbean Cruises Ltd (NYSE:RCL) which was down 7.62% to 243.89 at the close.

The top performers on the NASDAQ Composite were Mobilehealth Network Solutions (NASDAQ:MNDR) which rose 185.08% to 0.94, Xos Inc (NASDAQ:XOS) which was up 96.54% to settle at 6.25 and Sharps Technology Inc (NASDAQ:STSS) which gained 44.77% to close at 0.52.

The worst performers were Cycurion Inc (NASDAQ:CYCU) which was down 45.79% to 1.61 in late trade, Work Medical Technology Group Ltd (NASDAQ:WOK) which lost 44.86% to settle at 1.34 and Editas Medicine Inc (NASDAQ:EDIT) which was down 35.63% to 2.06 at the close.

Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1573 to 1184 and 100 ended unchanged; on the Nasdaq Stock Exchange, 2156 fell and 1116 advanced, while 151 ended unchanged.

Shares in Cycurion Inc (NASDAQ:CYCU) fell to all time lows; losing 45.79% or 1.36 to 1.61. Shares in Work Medical Technology Group Ltd (NASDAQ:WOK) fell to all time lows; falling 44.86% or 1.09 to 1.34.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was up 2.55% to 15.66.

Gold Futures for April delivery was up 0.66% or 19.40 to $2,955.50 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in April rose 0.60% or 0.43 to hit $72.53 a barrel, while the April Brent oil contract rose 0.64% or 0.49 to trade at $76.53 a barrel.

EUR/USD was up 0.78% to 1.05, while USD/JPY fell 1.23% to 149.60.

The US Dollar Index Futures was down 0.78% at 106.23.

Investing.com -- Shares of Dollar Tree (NASDAQ:DLTR) ticked up 0.8% following reports from Reuters that buyout firms, including Apollo Global Management (NYSE:APO) and Sycamore Partners, are showing interest in acquiring Family Dollar, a chain operated by the discount retailer. Brigade Capital Management is also said to be in the running for the purchase.

According to sources familiar with the matter, who requested anonymity due to the confidentiality of the discussions, the sale of Family Dollar could value the retailer at several billion dollars. However, they also cautioned that a deal is not imminent and Dollar Tree might decide against the sale. Additionally, there is the possibility of other suitors emerging for Family Dollar.

The news comes as Dollar Tree has been exploring the sale or spinoff of Family Dollar with the assistance of JPMorgan Chase (NYSE:JPM). The interest from these private equity firms has provided a slight boost to Dollar Tree's stock, as the market reacts to the potential divestiture of Family Dollar.

Investors are closely monitoring the situation, which could lead to significant changes in the company's structure and strategy. While the discussions are still in the early stages, the prospect of a sale has introduced a new dynamic to Dollar Tree's stock performance.

As the situation develops, market participants will be looking for further details on the potential acquisition and its implications for Dollar Tree's future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Thursday's market has witnessed notable fluctuations among stocks, with significant movements particularly observed in the mega-cap and large-cap categories. Stocks such as Alibaba-exch (BABA) and Palantir Technologies Inc (NASDAQ:PLTR) have experienced considerable shifts in their stock prices. Here's an overview of some of the major stock movers, ranging from mega-caps to small caps, based on intra-day stock movements.

Mega-Cap Movers ($200B+ Market Cap):

• Alibaba-exch (BABA): +8.55%
• Walmart Stores (NYSE:WMT): Walmart hikes annual dividend by 13 percent to $0.94 a share; -6.37%
• Palantir Technologies Inc (PLTR): -6.92%
• Morgan Stanley (NYSE:MS): -5.47%
• Goldman Sachs Group (NYSE:GS): -5.17%
• JP Morgan Chase (NYSE:JPM): -4.39%
• Oracle Corp (NYSE:ORCL): Salesforce (NYSE:CRM) in Talks With Microsoft (NASDAQ:MSFT), Oracle and Google (NASDAQ:GOOGL) About Cloud Deal to Handle AI - the Information; -2.94%
• American Express (NYSE:AXP): -2.56%
• Netflix, inc. (NASDAQ:NFLX): -1.98%
• Servicenow Inc (NYSE:NOW): NowVertical Completes Debt-to-Equity Conversions; -2.23%

Large-Cap Stock Movers ($10B-$200B Market Cap):

• Carvana (NYSE:CVNA): Carvana Announces Record Fourth Quarter and Full Year 2024 Results; -13.86%
• Fortress Transport Infrast (NASDAQ:FTAI): FTA Aviation refutes short seller claims after review; +14.46%
• Epam Systems Inc (NYSE:EPAM): EPAM Systems beats Q4 estimates, guides Q1 revenue above consensus; -14.97%
• Tempus AI (TEM): -10.69%
• Applovin (APP): -11.8%
• Taser Intl (NASDAQ:AXON): -11.29%
• Samsara (IOT): -9.44%
• Reinvent Technology Partners Y (AUR): -8.56%
• Grab Holdings (NASDAQ:GRAB): -9.36%
• Reddit (RDDT): -9.02%

Mid-Cap Stock Movers ($2B-$10B Market Cap):

• Unity Software Inc (NYSE:U): Unity Reports Fourth Quarter and Fiscal Year 2024 Financial Results; +27.39%
• Trupanion Inc (NASDAQ:TRUP): Trupanion shares falls 5% on bottom-line miss in Q4; -23.68%
• Freshpet Inc (NASDAQ:FRPT): Freshpet shares dip as Q4 earnings miss estimates; -16.9%
• Wildhorse Resource Development Corp (WRD): -14.94%
• Hasbro Inc (NASDAQ:HAS): Hasbro Launches Imaginative PLAY-DOH Barbie Playsets in Licensing Collaboration with Mattel (NASDAQ:MAT); +13.48%
• FTI Consulting Inc (NYSE:FCN): FTI Consulting Reports Fourth Quarter and Full Year 2024 Financial Results; -11.79%
• Clearwater Analytics Holdings (CWAN): Clearwater Analytics stock soars 8% as Q1 guidance exceeds estimates; +11.61%
• GDS Holdings Ltd (NASDAQ:GDS): +13.25%

Small-Cap Stock Movers ($300M-$2B Market Cap):

• Herbalife (NYSE:HLF): Herbalife stock surges 13% as earnings beat expectations; +43.77%
• Materialise (NASDAQ:MTLS): Materialise Reports Fourth Quarter and Full Year 2024 Results; -35.36%
• Jumia Technologies AG (NYSE:JMIA): Jumia Reports Fourth Quarter 2024 Results; -28.22%
• Nerdwallet (NRDS): NerdWallet shares surge 21% as Q4 earnings, revenue top estimates; -21.39%
• Amplitude (AMPL): Amplitude stock rating upgraded to Buy at DA Davidson; +22.62%
• Vimeo (NASDAQ:VMEO): Vimeo shares plunge 8% as guidance disappoints; -18.88%
• China Yuchai International Ltd (NYSE:CYD): China Yuchai seals engine tech deal with Vietnam's Kim Long Motor; +21.42%
• Mednax Inc (NYSE:MD): Pediatrix Medical (TASE:BLWV) Group Reports Fourth Quarter Results; +18.36%
• Candel Therapeutics (CADL): +20.78%
• PTIR (PTIR): -13.73%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Shares of FibroGen, Inc. (NASDAQ: NASDAQ:FGEN) surged 64% following the announcement of the sale of its China subsidiary to AstraZeneca (NASDAQ: NASDAQ:AZN) for an estimated $160 million. The transaction, which is expected to close by mid-2025, pending regulatory approval, will bolster FibroGen's financial position and extend its cash runway into 2027.

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will allow FibroGen to repay its term loan facility to investment funds managed by Morgan Stanley (NYSE:MS) Tactical Value, streamlining the company's capital structure.

FibroGen's CEO, Thane Wettig, highlighted the significance of the sale, noting it will enable the company to progress with its clinical development programs, particularly for FG-3246, a first-in-class antibody drug conjugate, and FG-3180, a companion PET imaging agent, in metastatic castration-resistant prostate cancer (mCRPC). Wettig expressed gratitude towards the China team for their dedication to patient care and the successful commercialization of roxadustat in China.

Post-sale, AstraZeneca will acquire all rights to roxadustat in China, where the drug leads in brand value share for treating anemia in chronic kidney disease and awaits a regulatory decision for chemotherapy-induced anemia. FibroGen retains rights to roxadustat in the U.S. and other markets not licensed to Astellas. The company is also planning an FDA meeting in the second quarter of 2025 to discuss the development of roxadustat for lower-risk myelodysplastic syndrome (LR-MDS), addressing a significant medical need.

Furthermore, FibroGen is preparing to initiate a Phase 2 monotherapy trial of FG-3246 in patients with mCRPC in the second quarter of 2025. BofA Securities, Inc. is serving as the exclusive financial advisor, and Ropes & Gray LLP is the legal advisor for FibroGen on this transaction.

This strategic divestiture provides FibroGen with a more focused approach to its pipeline and operations, potentially benefiting shareholders and patients alike as the company concentrates on its core development programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.